Barclays PLC Rhythm Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 106,397 shares of RYTM stock, worth $6.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,397

Previous 106,397 -0.0%

Holding current value

$6.15 Million

Previous $5.57 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$40.81 - $55.0 $2.15 Million - $2.9 Million	52,766 Added 98.39%	106,397 $5.57 Million
Q2 2024 Aug 14, 2024	SELL	$35.41 - $44.37 $2.62 Million - $3.28 Million	-73,905 Reduced 57.95%	53,631 $2.2 Million
Q1 2024 May 15, 2024	SELL	$39.12 - $52.44 $4.85 Million - $6.5 Million	-123,879 Reduced 49.27%	127,536 $5.53 Million
Q4 2023 Feb 15, 2024	BUY	$21.39 - $49.64 $217,194 - $504,044	10,154 Added 4.21%	251,415 $11.6 Million
Q3 2023 Nov 07, 2023	BUY	$15.81 - $27.8 $1.76 Million - $3.09 Million	111,033 Added 85.26%	241,261 $5.53 Million
Q2 2023 Aug 03, 2023	BUY	$16.32 - $21.15 $703,555 - $911,776	43,110 Added 49.48%	130,228 $2.15 Million
Q1 2023 May 04, 2023	SELL	$16.88 - $34.24 $1.61 Million - $3.27 Million	-95,481 Reduced 52.29%	87,118 $1.55 Million
Q4 2022 Feb 13, 2023	BUY	$22.21 - $30.25 $405,243 - $551,941	18,246 Added 11.1%	182,599 $5.32 Million
Q3 2022 Nov 03, 2022	BUY	$4.3 - $30.85 $666,770 - $4.78 Million	155,063 Added 1669.14%	164,353 $4.03 Million
Q2 2022 Aug 12, 2022	SELL	$3.12 - $12.25 $37,156 - $145,885	-11,909 Reduced 56.18%	9,290 $39,000
Q1 2022 May 16, 2022	SELL	$6.13 - $12.24 $197,815 - $394,984	-32,270 Reduced 60.35%	21,199 $245,000
Q4 2021 Feb 14, 2022	BUY	$8.62 - $13.9 $156,668 - $252,632	18,175 Added 51.5%	53,469 $533,000
Q3 2021 Nov 09, 2021	BUY	$11.68 - $20.72 $196,294 - $348,220	16,806 Added 90.9%	35,294 $461,000
Q2 2021 Aug 13, 2021	SELL	$18.52 - $22.55 $1.03 Million - $1.26 Million	-55,795 Reduced 75.11%	18,488 $363,000
Q1 2021 May 13, 2021	BUY	$20.25 - $39.49 $800,421 - $1.56 Million	39,527 Added 113.73%	74,283 $1.58 Million
Q4 2020 Feb 11, 2021	SELL	$21.17 - $32.61 $1.32 Million - $2.03 Million	-62,369 Reduced 64.22%	34,756 $1.03 Million
Q3 2020 Nov 12, 2020	SELL	$18.13 - $30.61 $85,682 - $144,662	-4,726 Reduced 4.64%	97,125 $2.11 Million
Q2 2020 Aug 12, 2020	BUY	$14.41 - $25.35 $117,110 - $206,019	8,127 Added 8.67%	101,851 $2.27 Million
Q1 2020 May 13, 2020	SELL	$13.16 - $22.9 $449,058 - $781,416	-34,123 Reduced 26.69%	93,724 $1.43 Million
Q4 2019 Feb 10, 2020	BUY	$19.53 - $25.5 $2.22 Million - $2.9 Million	113,881 Added 815.42%	127,847 $2.94 Million
Q3 2019 Nov 14, 2019	SELL	$18.62 - $24.51 $84,181 - $110,809	-4,521 Reduced 24.46%	13,966 $302,000
Q2 2019 Aug 14, 2019	SELL	$21.11 - $28.48 $21,869 - $29,505	-1,036 Reduced 5.31%	18,487 $406,000
Q1 2019 May 15, 2019	BUY	$24.76 - $31.66 $401,037 - $512,797	16,197 Added 486.98%	19,523 $536,000
Q4 2018 Feb 14, 2019	SELL	$24.11 - $31.34 $79,587 - $103,453	-3,301 Reduced 49.81%	3,326 $90,000
Q3 2018 Nov 14, 2018	BUY	$26.99 - $35.85 $143,100 - $190,076	5,302 Added 400.15%	6,627 $193,000
Q2 2018 Aug 14, 2018	SELL	$17.02 - $35.2 $48,387 - $100,073	-2,843 Reduced 68.21%	1,325 $41,000
Q1 2018 May 15, 2018	BUY	$19.9 - $32.25 $56,953 - $92,299	2,862 Added 219.14%	4,168 $84,000
Q4 2017 Feb 14, 2018	BUY	$22.0 - $30.51 $28,732 - $39,846	1,306	1,306 $38,000

Others Institutions Holding RYTM

# of Institutions

190

Shares Held

67.1M

Call Options Held

834K

Put Options Held

78.6K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.22B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account